https://biotechmorning.com/news/gsk-adc-phase-3-gynecologic-cancer Biotech Morning en 2026-04-13T14:15:08.758Z GSK's $31 Billion Bet Starts With a Cancer Most Companies Won't Touch https://biotechmorning.com/news/big-pharma-immunology-spring-cleaning Biotech Morning en 2026-04-13T14:14:23.300Z Big Pharma's Immunology Spring Cleaning Has Begun https://biotechmorning.com/news/regeneron-telix-radiopharmaceutical-deal Biotech Morning en 2026-04-13T14:13:44.037Z Regeneron Just Crashed the Hottest Party in Oncology https://biotechmorning.com/news/sclc-ifinatamab-deruxtecan-priority-review Biotech Morning en 2026-04-13T14:12:56.154Z The Cancer That Kills Fast Just Met a Drug That Moves Faster https://biotechmorning.com/news/allogene-off-the-shelf-car-t-lymphoma-results Biotech Morning en 2026-04-13T14:12:07.005Z The $10K Cancer Therapy That Just Passed Its Biggest Test https://biotechmorning.com/news/eye-cancer-uveal-melanoma-ideaya-darovasertib-fda Biotech Morning en 2026-04-13T14:11:14.474Z The Eye Cancer That Finally Got a Real Drug https://biotechmorning.com/news/seaport-hemab-ipo-filings-same-day Biotech Morning en 2026-04-13T14:10:31.528Z Two Biotechs Just Rang the IPO Bell on the Same Day https://biotechmorning.com/news/ras-undruggable-target-revolution-medicines-phase-3-win Biotech Morning en 2026-04-13T14:09:42.450Z The Protein That Stumped Cancer Researchers for 40 Years Just Lost https://biotechmorning.com/news/gilead-13-billion-six-weeks-acquisition-spree Biotech Morning en 2026-04-12T14:12:57.510Z Gilead Just Spent $13 Billion in Six Weeks. What Do They Know? https://biotechmorning.com/news/big-pharma-china-biopharma-out-licensing-surge-2026 Biotech Morning en 2026-04-12T14:12:11.241Z Big Pharma Can't Stop Shopping in China https://biotechmorning.com/news/avalyn-pharma-ipo-lung-disease-bet Biotech Morning en 2026-04-12T14:11:25.851Z The Lung Disease Bet That's Banking on a $4 Billion Market Nobody's Cracked https://biotechmorning.com/news/oricell-110m-car-t-solid-tumors-ipo Biotech Morning en 2026-04-12T14:10:42.491Z The $110M Bet That CAR-T Can Finally Crack Solid Tumors https://biotechmorning.com/news/fda-rejects-replimune-rp1-melanoma-second-time Biotech Morning en 2026-04-12T14:10:03.125Z The FDA Just Rejected This Cancer Therapy. Again. https://biotechmorning.com/news/glp1-pill-foundayo-oral-obesity-drug-fda-approval Biotech Morning en 2026-04-12T14:09:22.453Z The GLP-1 Pill That Could Make Needles Obsolete https://biotechmorning.com/news/neurocrine-soleno-acquisition-prader-willi Biotech Morning en 2026-04-12T14:08:37.660Z Neurocrine Just Bet $2.9 Billion on a Disease Most People Have Never Heard Of https://biotechmorning.com/news/biotech-ipo-drought-over-q1-2026 Biotech Morning en 2026-04-12T14:07:58.532Z Biotech's IPO Drought Is Over. The Rain Is Coming in Buckets.